1426174-38-0
Chemical Structure
Cefadroxil-d4 hydrate
Synonym(s): BL-S 578-d4 hydrate
- CAS No.: 1426174-38-0
- Formula:C16H15D4N3O6S
- Molecular Weight:385.43
IUPAC Name: (6R,7R)-7-((R)-2-amino-2-(4-hydroxyphenyl-2,3,5,6-d4)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
InChIKey: NBFNMSULHIODTC-AUTKPGNWSA-N
SMILES: OC(C1=C(C)CS[C@@]([C@@H]2NC([C@@H](C3=C([2H])C([2H])=C(C([2H])=C3[2H])O)N)=O)([H])N1C2=O)=O.O
Biological Activity: Cefadroxil-d4 (hydrate) is the deuterium labeled Cefadroxil hydrate (HY-B1190A). Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cefadroxil-d4 hydrate | Cefadroxil-d4 (hydrate) is the deuterium labeled Cefadroxil hydrate (HY-B1190A). Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cefadroxil hydrate (Standard) | ≥98% | Cefadroxil (hydrate) (Standard) is the analytical standard of Cefadroxil hydrate (HY-B1190A). This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cefadroxil hydrate | 99.0% | Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Buck RE, et al. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977 Feb;11(2):324-30. [Content Brief]
- [3]. Posada MM, et al. Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. Pharm Res. 2013 Apr;30(4):1017-25. [Content Brief]
- [4]. Hu Y, et al. Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 mice. Biochem Pharmacol. 2016 May 1;107:81-90. [Content Brief]
- [5]. Han CJ, et al. Antinociceptive effects of cefadroxil and ceftriaxone in experimental animal models of pain. Neuro Endocrinol Lett. 2023 Jul 28;44(5):309-320. [Content Brief]
- [6]. Tan Z, et al. Physiologically Based Pharmacokinetic Modeling of Cefadroxil in Mouse, Rat, and Human to Predict Concentration-Time Profile at Infected Tissue. Front Pharmacol. 2021 Dec 23;12:692741. [Content Brief]
- [7]. Chisholm DR, et al. Therapeutic efficacy of cefadroxil and cephalexin for pneumonia in a rat test model. Antimicrob Agents Chemother. 1986 Jul;30(1):105-9. [Content Brief]
- [8]. Chen X, et al. Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study. Biochem Pharmacol. 2017 May 1;131:89-97. [Content Brief]
